1	Evaluation of a new dengue 3 controlled human infection model for use in the evaluation of candidate
2	dengue vaccines.
3	Pierce KK 1* , Whitehead SS 2 , Diehl SA 3 , Naro G 3 , Carmolli MC 3 , He H 4 , Tibery, CM 5 , Sabundayo BP 4 ,
4	Kirkpatrick BD ^{1,3} , Durbin AP ⁴ .
5	Vaccine Testing Center, Departments of Medicine ¹ and Microbiology and Molecular Genetics ³ ,
6	University of Vermont Larner College of Medicine, Burlington, Vermont , ² National Institute of Allergy
7	and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, 4 Johns Hopkins Bloomberg
8	School of Public Health, Baltimore, Maryland, 5 Currently at National Institutes of Health, Bethesda,
9	Maryland
10	*Corresponding Author: Kristen K. Pierce
11	Email: Kristen.pierce@uvmhealth.org
12	Word Count: Abstract=59, text=1752
13	
14	Abstract:
15	All four serotypes of dengue virus (DENV) cause the full spectrum of disease. Therefore, vaccines must
16	protect against all serotypes. To evaluate candidate vaccines, a human challenge model of dengue
17	serotype 3 (rDEN30 Δ 30) was developed. All challenge virus recipients safely met the primary endpoint
18	of viremia and secondary endpoints of rash and seroconversion to DENV-3.
19	Keywords: Controlled Human Infection Model, Dengue, Vaccine
20	Running title: DENV-3 controlled human infection model
21	

22

23

24 Background

25	Infections caused by dengue virus (DENV) are among the most prevalent mosquito borne diseases
26	globally. The World Health Organization (WHO) estimates that dengue viruses cause over 50 million
27	cases of dengue fever (DF) and 500,000 cases of severe disease: dengue hemorrhagic fever or dengue
28	shock syndrome, annually [1]. Effective therapeutic agents for dengue disease do not exist, making
29	vaccine development vital. Disease can be caused by any of four serotypes, DENV1-4, which complicates
30	vaccine development. Infection with one serotype confers long lasting homotypic (serotype-specific)
31	clinical immunity and short-lived heterotypic immunity to the other three serotypes. Although severe
32	disease can occur following primary infection, studies have shown that most severe dengue cases occur
33	in subsequent infections with a serotype different (heterotypic) from the first infection [2]. This
34	phenomenon is thought to be mediated by antibody dependent enhancement of infection (ADE):
35	whereby non-neutralizing antibody from the primary serotype binds but cannot neutralize the second
36	infecting serotype, leading to enhanced cellular entry via the Fc γ receptor and viral replication [3]. For
37	this reason, an ideal dengue vaccine would achieve a homotypic response to all four serotypes.
38	Several live attenuated tetravalent dengue vaccines are in development. The only licensed vaccine,
39	Dengvaxia [®] , remains limited in its use due to excess levels of dengue hospitalization following a
40	subsequent dengue infection in individuals who were dengue sero-naïve at vaccination [4, 5].
41	Given these safety concerns, testing of candidate vaccines in humans must be done with great caution.
42	Human infection models are an established tool for early evaluation of vaccine efficacy. The dengue
43	controlled human infection model (D-CHIM) developed by our team uses well-studied, naturally

44	attenuated dengue strains to elicit safe, low-level dengue infection in healthy volunteers. Our D-CHIM is
45	an infection model with viremia and rash as clinical endpoints rather than a disease model which
46	induces symptomatic illness. To use the D-CHIM for vaccine candidate evaluation, individuals receive a
47	dengue vaccine or placebo and are subsequently inoculated with the challenge strain to determine the
48	protection provided by vaccination. Our first D-CHIM used a recombinant DENV-2 (Tonga) as the
49	challenge strain to assess the protective efficacy of the TV003 vaccine. Six months after vaccination,
50	TV003 elicited complete protection against DENV-2 challenge, whereas all placebo recipients
51	demonstrated infectious DENV-2 (Tonga) viremia following challenge [6].
52	The success of the DENV-2 D-CHIM compelled us to develop challenge strains for the other DENV
53	serotypes to evaluate the broad protective efficacy of the NIH tetravalent vaccines, TV003 and TV005.
54	We developed a recombinant DENV-3 challenge strain, rDEN3 Δ 30, for use in D-CHIM studies of
55	candidate dengue vaccines.
56	DENV-3 Sleman/78 is the parent virus for both the attenuated DENV-3 (rDEN30 Δ 30/31) vaccine
	DENV-3 Sleman/78 is the parent virus for both the attenuated DENV-3 (rDEN30 Δ 30/31) vaccine component of TV003 and TV005 and the rDEN3 Δ 30 challenge strain described herein. DENV-3
56	
56 57	component of TV003 and TV005 and the rDEN3 Δ 30 challenge strain described herein. DENV-3
56 57 58	component of TV003 and TV005 and the rDEN3 Δ 30 challenge strain described herein. DENV-3 Sleman/78 was isolated during a dengue outbreak in 1978 in the Sleman district in Central Java [7].
56 57 58 59	component of TV003 and TV005 and the rDEN3Δ30 challenge strain described herein. DENV-3 Sleman/78 was isolated during a dengue outbreak in 1978 in the Sleman district in Central Java [7]. During that year, illness was mild, mostly observed in children under 15 years of age, with no dengue
56 57 58 59 60	component of TV003 and TV005 and the rDEN3Δ30 challenge strain described herein. DENV-3 Sleman/78 was isolated during a dengue outbreak in 1978 in the Sleman district in Central Java [7]. During that year, illness was mild, mostly observed in children under 15 years of age, with no dengue associated deaths. In contrast, the DENV-3 strain (Bantul), which had circulated the previous year, led to
56 57 58 59 60 61	component of TV003 and TV005 and the rDEN3Δ30 challenge strain described herein. DENV-3 Sleman/78 was isolated during a dengue outbreak in 1978 in the Sleman district in Central Java [7]. During that year, illness was mild, mostly observed in children under 15 years of age, with no dengue associated deaths. In contrast, the DENV-3 strain (Bantul), which had circulated the previous year, led to significant illness and hospitalization. The viremia for the Sleman strain was lower than the previous
56 57 58 59 60 61 62	component of TV003 and TV005 and the rDEN3Δ30 challenge strain described herein. DENV-3 Sleman/78 was isolated during a dengue outbreak in 1978 in the Sleman district in Central Java [7]. During that year, illness was mild, mostly observed in children under 15 years of age, with no dengue associated deaths. In contrast, the DENV-3 strain (Bantul), which had circulated the previous year, led to significant illness and hospitalization. The viremia for the Sleman strain was lower than the previous Bantul strain and is considered to be naturally attenuated. The rDEN3Δ30 virus was originally developed
56 57 58 60 61 62 63	component of TV003 and TV005 and the rDEN3Δ30 challenge strain described herein. DENV-3 Sleman/78 was isolated during a dengue outbreak in 1978 in the Sleman district in Central Java [7]. During that year, illness was mild, mostly observed in children under 15 years of age, with no dengue associated deaths. In contrast, the DENV-3 strain (Bantul), which had circulated the previous year, led to significant illness and hospitalization. The viremia for the Sleman strain was lower than the previous Bantul strain and is considered to be naturally attenuated. The rDEN3Δ30 virus was originally developed as a candidate DENV-3 vaccine. However, in nonhuman primate models, rDEN3Δ30 was not significantly
56 57 58 60 61 62 63 64	component of TV003 and TV005 and the rDEN3Δ30 challenge strain described herein. DENV-3 Sleman/78 was isolated during a dengue outbreak in 1978 in the Sleman district in Central Java [7]. During that year, illness was mild, mostly observed in children under 15 years of age, with no dengue associated deaths. In contrast, the DENV-3 strain (Bantul), which had circulated the previous year, led to significant illness and hospitalization. The viremia for the Sleman strain was lower than the previous Bantul strain and is considered to be naturally attenuated. The rDEN3Δ30 virus was originally developed as a candidate DENV-3 vaccine. However, in nonhuman primate models, rDEN3Δ30 was not significantly attenuated compared to the parent virus DENV-3 Sleman/78 [8]. rDEN3Δ30 induced viremia in 100% of

Here we describe the first evaluation of rDEN3Δ30 in healthy, flavivirus-naïve human volunteers and the
potential for its use in future D-CHIM studies.

70 Methods

71 This study was conducted under IND application (IND # 16765) at the Center for Immunization Research,

72 Johns Hopkins School of Public Health and the Vaccine Testing Center, University of Vermont College of

73 Medicine, and was approved by their Institutional Review Boards and Biosafety Committees. The

74 National Institute of Allergy and Infectious Diseases (NIAID) Intramural Data Safety Monitoring Board

reviewed all study data. Clinicaltrials.gov NCT02684383.

76 <u>Study population</u>. Volunteers were recruited from Baltimore, MD, and Burlington, VT. Informed consent

77 was obtained. Similar to previously published studies, inclusion criteria included: healthy subjects age

78 18-50, negative serology for Hepatitis B, C and HIV, no evidence of prior dengue infection or other

flaviviruses, and normal screening values for liver and renal function, urinalysis and coagulation [9].

80 Women of childbearing potential had a negative pregnancy test at screening and on inoculation day and

81 were required to use a reliable method of contraception for study duration. Following receipt of the

test article (rDEN3Δ30 or placebo), subjects recorded their temperature three times daily.

83 <u>Study design</u>

A randomized double-blind controlled trial was performed with 14 subjects. Randomization was 5:2, to
receive either 3 log₁₀ PFU of rDEN3Δ30 or placebo (L-15) as a 0.5 mL subcutaneous injection. To
adequately power for viremia only 10 subjects were required to receive DENV-3. Following dosing,
volunteers returned to the clinic every other day for the first 2 weeks and then on study days 21, 28, 56,
90, and 180 for clinician assessment, which included physical exam and documentation of clinical signs
and symptoms. During the first 2 weeks volunteers were contacted via phone on non-clinic days to
review symptoms and to check for fever. During clinic visits, blood was obtained for virus titration and

91	safety laboratory studies (CBC, ALT, coagulation studies). Neutralizing antibody was measured at days 0
92	(pre-vaccination), 28, 56, 90 and 180 using the 50% plaque reduction neutralization titer (PRNT $_{50}$) assay
93	with DENV-3 Sleman/78 as the target virus [10]. Seroconversion was defined as \geq 4-fold rise in
94	neutralizing antibody titer at day 90 compared to day 0. Viremia was assessed as described using
95	culture-based method [10]. The frequency of clinical signs and symptoms was compared between
96	rDEN3 Δ 30 and placebo recipients and their statistical significance was determined using Fisher's Exact
97	test.
98	Results
99	14 subjects were enrolled, five (35%) were women. At each site five subjects received rDEN3 Δ 30 and
100	two subjects received placebo (diluent). Mean age was 34 years (range 24-47 years).
101	All 10 subjects who received rDEN3 Δ 30 (100%) met the primary endpoint of viremia and 8 (80%) had a
102	dengue-like rash. Rash was only seen in rDEN3 Δ 30 recipients and was dengue-like in appearance
103	(diffuse, maculopapular, and present over the trunk and extremities). It was observed approximately
104	four days after challenge, and completely resolved within 7-10 days. Among the eight rash
105	presentations, five were graded as moderate and three were mild. Transient, asymptomatic neutropenia
106	and thrombocytopenia were seen in one and two volunteers, respectively.
107	Individual viremia data are presented in Figure 1A. The mean peak viremia titer in rDEN3 Δ 30 recipients
108	was 1.8 log ₁₀ PFU/mL (range 0.5-2.1); mean day of onset was 4.6 days (range 3-6 days) with a mean
109	duration of 3.4 days. All 10 rDEN3 Δ 30 recipients seroconverted to DENV-3; the PRNT ₅₀ to DENV-3
110	peaked at day 28. Although titers declined slightly, they remained high at day 180 with a GMT of 143
111	(range 44-392). Peak low level heterotypic antibodies to serotypes DENV-1 and -2 were seen in
112	rDEN3∆30 recipients (Figure 1B).

Overall, the DENV-3 inoculation was well-tolerated. Fever was not observed in any volunteer. Local
reactogenicity in the rDEN3Δ30 group included injection site erythema (10%) and injection site
induration (20%). The frequency of clinical signs and symptoms other than rash were not significantly
different between the groups (Table 1). Of the 86 reported events, 77 (89.5%) were considered mild;
the remainder were graded as moderate. The only moderate events deemed to be related to rDEN3Δ30
or placebo were rash and fatigue.

119 Discussion

120 Important requirements for development of a safe dengue vaccine include the need to achieve a robust 121 and balanced immune response protective against all four serotypes while maintaining an acceptable 122 reactogenicity profile. The implication of an incomplete or imbalanced response, as recently seen in 123 long-term follow up of Dengvaxia[®] recipients, is the possibility the vaccine may predispose to more 124 severe disease upon subsequent exposure to DENV years following vaccination [4]. Although 125 neutralizing antibody is thought to be a mediator of protection, titers of neutralizing antibody induced 126 by Dengvaxia[®] were not indicative of protection against dengue [11]. Use of the D-CHIM to evaluate the 127 protective efficacy of candidate vaccines offers additional assurances of serotype-specific protection in 128 advance of phase III testing in large endemic-setting populations.

Our study demonstrated rDEN3Δ30 is highly infectious and immunogenic yet induces mild to moderate clinical signs in all inoculated volunteers. The infectivity and safety profile of the DENV-3 challenge virus makes it ideal for use in CHIM studies to evaluate candidate vaccines. As seen in the DENV-2 CHIM, we targeted induction of detectable viremia in a high percentage of subjects, with peak titers that elicited only mild to moderate clinical signs [6]. Prior to our model, another research team performed a Dengue 3 CHIM as a disease model which caused symptomatic dengue-like illness. Volunteers in that study experienced fever for several days, transaminitis, and one subject had evidence of perihepatic and

136	pericardial effusions by ultrasound [12]. In our study, 100% of rDEN3 Δ 30 recipients had detectable
137	viremia and seroconverted to DENV-3 based on neutralizing antibody; dengue-like rash was seen in
138	eight of 10 volunteers (80%). Neither fever, transaminitis, nor effusions were observed in any volunteer.
139	Given that 75% of DENV infections do not present for clinical care, we propose that the endpoints of
140	viremia and rash are relevant to the course of natural infection and are reproducible targets upon which
141	candidate vaccines can be safely evaluated.
142	When compared to our DENV-2 D-CHIM, rDEN3 Δ 30 infection induced a lower mean peak virus titer
143	(1.77 \log_{10} PFU/mL) vs. rDEN2 Δ 30 (2.3 \log_{10} PFU/mL). Nevertheless, rDEN3 Δ 30 induced rashes of
144	moderate severity in 50% of challenge volunteers. This possible disconnect of peak viremia titer and
145	rash severity will be monitored closing in subsequent trials.
145 146	rash severity will be monitored closing in subsequent trials. The rDEN3∆30 CHIM is an important new tool for evaluating candidate dengue vaccines in advance of
146	The rDEN3Δ30 CHIM is an important new tool for evaluating candidate dengue vaccines in advance of
146 147	The rDEN3∆30 CHIM is an important new tool for evaluating candidate dengue vaccines in advance of phase III efficacy trials in endemic populations. Its safety and infectivity profiles are acceptable and
146 147 148	The rDEN3 Δ 30 CHIM is an important new tool for evaluating candidate dengue vaccines in advance of phase III efficacy trials in endemic populations. Its safety and infectivity profiles are acceptable and because of rDEN3 Δ 30's high infectivity, efficacy studies can be powered for significance with relatively
146 147 148 149	The rDEN3 Δ 30 CHIM is an important new tool for evaluating candidate dengue vaccines in advance of phase III efficacy trials in endemic populations. Its safety and infectivity profiles are acceptable and because of rDEN3 Δ 30's high infectivity, efficacy studies can be powered for significance with relatively few subjects. We argue that, in light of the concerns raised with the most recent large scale Phase III
146 147 148 149 150	The rDEN3 Δ 30 CHIM is an important new tool for evaluating candidate dengue vaccines in advance of phase III efficacy trials in endemic populations. Its safety and infectivity profiles are acceptable and because of rDEN3 Δ 30's high infectivity, efficacy studies can be powered for significance with relatively few subjects. We argue that, in light of the concerns raised with the most recent large scale Phase III dengue vaccine trials, the CHIM provides a platform to test vaccine safety and efficacy on a smaller scale

154 <u>Funding</u>

155 This work was supported by the National Institute of Allergy and Infectious Disease Intramural Research

156 Program, National Institutes of Health [contract no. HHSN272200900010C]

158 Acknowledgments

- 159 Dengue virus strains were provided by the Laboratory of Infectious Diseases, NIH. We would like to
- 160 thank all of the dedicated volunteers, and the excellent research nurses and staff at the JHU CIR and
- 161 UVM VTC Clinical Research Centers. In addition, the authors would like to thank the Office of Clinical
- 162 Research Policy and Regulatory Operations at the NIH for providing the regulatory oversight.

163 Potential Conflicts of Interest


- 164 None of the above authors have any reported conflict of interest. All authors have submitted the ICMJE
- 165 form for potential conflicts of interest. Conflicts that the editors of the manuscript consider relevant to
- 166 the content of the manuscript have been disclosed.

168 FIGURE LEGEND

- 169 **Figure 1 (A)** rDEN3Δ30 was cultured from serum samples collected on the indicated days. Virus was
- detected by culture in Vero cells as described in the methods. Time course of viremia for the 10
- individuals administered rDEN3 Δ 30 is shown. The lower limit of detection is 0.5 log₁₀ PFU/mL of serum.
- 172 PFU, plaque forming unit. (B) Serum was collected from the 10 infected individuals on study days 0, 28,
- 173 56, 90, and 180. The peak PRNT₅₀ achieved through study day 90 for each of the four DENV serotypes is
- shown for all individuals who developed a $PRNT_{50} > 1:5$ (limit of detection). The geometric mean peak
- titer with SD is indicated.
- 176
- 177
- 178
- 179
- 180
- 181


182

184 Figure 1A:



185





189

		DEN3∆30 (n=10)	Placebo (n=4)	p-value (1-sided)
Local				
	Erythema	10.0%	0.0%	0.7143
	Tenderness	0.0%	0.0%	n/a
	Pain	0.0%	0.0%	n/a
	Pruritus	0.0%	0.0%	n/a
	Induration	20.0%	0.0%	0.4945
System	nic			
	Viremia	100.0%	0.0%	0.0010
	Fever	0.0%	0.0%	n/a
	Headache	60.0%	75.0%	0.8741
	Rash	80.0%	0.0%	0.0150
	Neutropenia ^b	10.0%	0.0%	0.7143
	Elevated ALT	0.0%	0.0%	n/a
	Myalgia	40.0%	25.0%	0.5455
	Arthralgia	10.0%	0.0%	0.7143
	Retro-orbital Pain	50.0%	25.0%	0.4056
	Photophobia	10.0%	25.0%	0.9341
	Fatigue	50.0%	50.0%	0.7203
	Nausea	10.0%	50.0%	0.9890
	Prolonged PT	0.0%	0.0%	n/a
	Prolonged PTT	0.0%	0.0%	n/a
	Hemoglobin Decreased	10.0%	0.0%	0.7143
	Thrombocytopenia ^c	20.0%	0.0%	0.4945
а.	Fisher's Exact test, p value r	not corrected for multip	le comparisons	
b.	Neutropenia was defined as			
с.	Thrombocytopenia was def	ined as $\leq 120,000/\text{mm}^3$		

190 Table 1: Clinical signs and symptoms following a single dose of rDEN3Δ30 compared with placebo

199	
200	
201	References
202 203	1. WHO. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd ed. Geneva: WHO, 1997 .
204 205	2. Monath T, Heinz F. Flaviviruses. In: Fields BN, Knipe DM, Howley PM, et al., eds. Fields Virology. third ed. Vol. 1. Philadelphia: Lipincott-Raven, 1996 :961-1034.
206 207	3. Halstead SB, Chow J, Marchette NJ. Immunologic enhancement of dengue virus replication. Nature New Biology 1973 ; 243:24-6. PMID:
208 209	4. Sridhar S, Luedtke A, Langevin E, et al. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. N Engl J Med 2018 ; 379:327-40. PMID: 29897841.
210 211 212	5. Capeding MR, Tran NH, Hadinegoro SRS, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. The Lancet 2014 ; 384:1358-65. PMID: 25018116.
213 214 215	6. Kirkpatrick BD, Whitehead SS, Pierce KK, et al. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Sci Transl Med 2016 ; 8:330ra36. PMID: 27089205.
216 217	7. Gubler DJ, Suharyono W, Lubis I, Eram S, Gunarso S. Epidemic dengue 3 in central Java, associated with low viremia in man. Am J Trop Med Hyg 1981 ; 30:1094-9. PMID:
218 219 220	8. Blaney JE, Jr., Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg 2004 ; 71:811-21. PMID: 15642976.
221 222 223	9. Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg 2001 ; 65:405-13. PMID: 11716091.
224 225 226	10. Durbin AP, Kirkpatrick BD, Pierce KK, et al. A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double- blind Clinical Trial. J Infect Dis 2013 ; 207:957-65. PMID: 23329850. 3571448.
227 228 229	11. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live- attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012 ; 380:1559-67. PMID: 22975340.
230 231	12. Lyons AG. The Human Dengue Challenge Experience at the Walter Reed Army Institute of Research. Journal of Infectious Diseases 2014 ; 209:S49-S55. PMID: